Vitrolife named as winner of the 2012 SwedenBIO Award

Vitrolife has been named as the winner of the 2012 SwedenBIO Award. The prize is
awarded by SwedenBIO, which is an association of member companies with the aim
of promoting growth in the Life Science industry in Sweden. State Secretary
Håkan Ekengren today awarded the distinction to Vitrolife at SwedenBIO’s Annual
Meeting.
The jury’s statement was as follows: “Through its innovative products and focus
on the customer, Vitrolife has succeeded in building up a profitable and rapidly
growing company that has attained international positions and international
recognition. The winner has 37 quarters in a row of revenue growth as well as
important and promising research. The jury particularly wishes to mention that
Vitrolife has charted the world’s previously unknown regulatory territory and
left a clear map with regard to IVF.”

The prize has been instituted to draw attention to prominent companies and
leaders within the Life Science industry. This year’s prize is the sixth to be
awarded and previous winners are Aerocrine, BioInvent, Cellavision, Medivir and
Gyros.

“We are extremely proud to have been awarded this distinction. We see the award
as a result of our many years of work to contribute to life being created and
prolonged. For us this prestigious prize means a strengthening of our standing,
which we hope will lead to further successes," says Thomas Axelsson, CEO of
Vitrolife.

May 24, 2012

Gothenburg, Sweden
VITROLIFE AB (publ)
Thomas Axelsson

CEO
Queries should be addressed to:

Thomas Axelsson, CEO, phone 46 708 17 99 76

Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on May
24, 2012 at 17:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global
biotechnology/medical device Group that works in the areas of Fertility and
Transplantation. The Fertility (http://www.vitrolife.com/en/Fertility/) product
area works with nutrient solutions (media), cryopreservation products and
advanced consumable instruments such as needles and pipettes, for the treatment
of human infertility. Work is also carried out to enable the use and handling of
stem cells for therapeutic purposes. The
Transplantation (http://www.xvivoperfusion.com/transplantation/) product area
works with solutions and systems for assessing and preserving organs outside the
body, so as to be able to select usable organs and keep them in optimal
condition pending transplantation.

Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220
employees and its products are sold in almost 90 markets. The company is
headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife
share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on
NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/